immuno-oncology

News

David Campbell, founder, president and CEO of Janux

Janux plans $200m offer on back of prostate cancer readout

Buoyed by data from a trial of its T-cell engager (TCE) therapy in prostate cancer that almost tripled its share price, Janux Therapeutics has moved quickly to file a stoc

News

New era for cell therapy as FDA OKs first for solid tumours

Iovance Biotherapeutics has carved out a piece of biotech history, becoming the first company to win FDA clearance for a cell therapy used to treat a solid tumour.

News

Gilead’s CD47 woes continue, this time in solid tumours

Just a week after dropping the development of its CD47-targeting antibody magrolimab in blood cancers, Gilead Sciences has paused enrolment in clinical trials of the drug

News

Astellas pledges $800m to Kelonia CAR-T alliance in cancer

Astellas has signed an R&D and licensing deal with Kelonia Therapeutics that aims to develop CAR-T therapies for cancer that will push the boundaries of what can be ac

News

BioNTech adds CAR-T manufacturing with $250m Autolus deal

Germany’s BioNTech has taken a $200 million stake in Autolus in a private placement that will allow it to tap into the UK company’s manufacturing capacity for CAR-T therap

News

First patient treated with Moderna's PD-1/IDO1 cancer shot

The first patient has been treated in a phase 1/2 clinical trial of an experimental Moderna vaccine designed to generate antibodies against PD-L1 and IDO1 – two targets th

Janux plans $200m offer on back of prostate cancer readout

New era for cell therapy as FDA OKs first for solid tumours

Gilead’s CD47 woes continue, this time in solid tumours

Astellas pledges $800m to Kelonia CAR-T alliance in cancer

BioNTech adds CAR-T manufacturing with $250m Autolus deal

First patient treated with Moderna's PD-1/IDO1 cancer shot

Allergy Tx plots grass pollen jab launch after German okay

The AI imperative: Establishing the standard for modern clin...

immuno-oncology

Editor's Picks